Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

MLA

LaCroix, Andrea Z., et al. “Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women.” Journal of the National Cancer Institute, vol. 102, no. 22, Nov. 2010, pp. 1706–15. EBSCOhost, https://doi.org/10.1093/jnci/djq415.

APA

LaCroix, A. Z., Powles, T., Osborne, C. K., Wolter, K., Thompson, J. R., Thompson, D. D., Allred, D. C., Armstrong, R., Cummings, S. R., Eastell, R., Ensrud, K. E., Goss, P., Lee, A., Neven, P., Reid, D. M., Curto, M., & Vukicevic, S. (2010). Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. Journal of the National Cancer Institute, 102(22), 1706–1715. https://doi.org/10.1093/jnci/djq415

Chicago

LaCroix, Andrea Z, Trevor Powles, C Kent Osborne, Kevin Wolter, John R Thompson, David D Thompson, D Craig Allred, et al. 2010. “Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women.” Journal of the National Cancer Institute 102 (22): 1706–15. doi:10.1093/jnci/djq415.